NEW YORK, Feb. 25, 2020
/PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today
announced its attendance at the AI & ML Drug Discovery
Summit. The AI-ML in Drug Development Summit is the only
conference to bring together industry leaders, technology experts
and academics focused on augmenting the R&D processes through
the use of Artificial Intelligence and Machine Learning. The event,
scheduled for February 24-26, 2020 at
the DoubleTree by Hilton Hotel San Diego - Mission Valley, brings
together industry leaders and academics who are developing and
implementing technological solutions for some of pharma's greatest
problems.
Mr. Anthony Hayes, CEO of Spherix
stated, "We believe that the use of machine learning and artificial
intelligence in drug discovery and development will be an important
part of the future for this industry. We are excited to be a
part of this conference as we continue to work towards becoming a
diversified biopharmaceutical company."
The AI-ML in Drug Discovery & Development Summit is the only
conference to bring together industry leaders, technology experts
and academics focused on augmenting R&D processes. The
three-day conference features case studies, panels and varied
networking opportunities. The 2020 agenda will reflect the strides
taken by the community over the past year and mistakes made as well
as forming the future of machine learning solutions in the R&D
process.
About Spherix
Spherix Incorporated, a Delaware corporation (the "Company"), was
initially formed in 1967 and is currently a biotechnology company
with a diverse portfolio of small-molecule anti-cancer
therapeutics. The Company's platform consists of patented
technology from leading universities and researchers and we are
currently in the process of developing an innovative therapeutic
drug platform through strong partnerships with world renowned
educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of
therapeutics includes therapies for pancreatic cancer, acute
myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In
addition, we are constantly seeking to grow our pipe to treat unmet
medical needs in oncology
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its patent business contained therein. Thus,
actual results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
Spherix:
Phone: 212-745-1373
Email: investorrelations@spherix.com
www.spherix.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/spherix-attends-artificial-intelligence-and-machine-learning-pharmaceutical-development-conference-301010702.html
SOURCE Spherix Incorporated